DR. JEAN MARIE WANG MENGOLI, O.D.
Optometry at Vandever Ave, San Diego, CA
License number
California 11975T
Category
Optometry
Type
Optometrist
Address
Address
4405 Vandever Ave, San Diego, CA 92120
Phone
(503) 936-4136
Personal information
See more information about JEAN MARIE WANG MENGOLI at radaris.comName
Address
Phone
54 Parnell Ave, Daly City, CA 94015
599 Eaton Dr, Pasadena, CA 91107
5976 Lily Rock Dr, Fontana, CA 92336
5529 Feather Ct, Castro Valley, CA 94552
4576 Niland St, Union City, CA 94587
Professional information
Scientist At Pfizer
Position:
scientist at Pfizer
Location:
Greater San Diego Area
Industry:
Biotechnology
Work:
Pfizer
-
scientist
Dielectrophoretic Particle Sorter
US Patent:
2006017, Aug 10, 2006
Filed:
Nov 28, 2005
Appl. No.:
11/288016
Inventors:
Hyongsok Soh - Santa Barbara CA, US
Jean Wang - San Diego CA, US
Unyoung Kim - Goleta CA, US
Xiaoyuan Hu - San Jose CA, US
Jiangrong Qian - Goleta CA, US
Carl Meinhart - Santa Barbara CA, US
Jean Wang - San Diego CA, US
Unyoung Kim - Goleta CA, US
Xiaoyuan Hu - San Jose CA, US
Jiangrong Qian - Goleta CA, US
Carl Meinhart - Santa Barbara CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/00, C12Q 1/70, H03C 3/09
US Classification:
435004000, 435005000, 204450000, 332128000
Abstract:
Provided are methods, devices and systems that utilize dielectrophoretic forces to separate a target species from a plurality of species in a sample.
Jean M Wang, San Diego CA - OD (Doctor of Optometry)
Specialties:
Optometry
Address:
4405 Vandever Ave, San Diego 92120
Languages:
English
Strategy For Leukemia Therapy
US Patent:
2007029, Dec 27, 2007
Filed:
Jun 29, 2007
Appl. No.:
11/771453
Inventors:
Jean Wang - San Diego CA, US
Paolo Vigneri - Catania, IT
Paolo Vigneri - Catania, IT
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/366, A61K 49/00
US Classification:
514275000, 424780000, 435375000, 424009200, 514460000
Abstract:
The chimeric Bcr-Abl oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). In the cytoplasm, the protein transduces a growth signal that is responsible for overexpansion of cells. In the nucleus, the protein induces apoptosis. The invention is a method of treating cancer/killing Bcr-Abl expressing cells by inducing the translocation of Bcr-Abl to the nucleus to activate the apoptotic pathway in cancer cells.
Strategy For Leukemia Therapy
US Patent:
2003016, Aug 28, 2003
Filed:
Dec 27, 2002
Appl. No.:
10/312918
Inventors:
Jean Wang - San Diego CA, US
Paolo Vigneri - Catania, IT
Paolo Vigneri - Catania, IT
International Classification:
A61K048/00
US Classification:
514/044000, 424/093200
Abstract:
The chimeric Bcr-Abl oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). In the cytoplasm, the protein transduces a growth signal that is responsible for overexpansion of cells. In the nucleus, the protein induces apoptosis. The invention is a method of treating cancer/killing Bcr-Abl expressing cells by inducing the translocation of Bcr-Abl to the nucleus to activate the apoptotic pathway in cancer cells.